Passage Bio
PASG
108 hedge funds and large institutions have $133M invested in Passage Bio in 2022 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 34 increasing their positions, 30 reducing their positions, and 15 closing their positions.
338% more call options, than puts
Call options by funds: $35K | Put options by funds: $8K
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
13% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 30
9% more funds holding
Funds holding: 99 → 108 (+9)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.08% less ownership
Funds ownership: 4.04% → 3.96% (-0.08%)
52% less capital invested
Capital invested by funds: $278M → $133M (-$144M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$2M |
| 2 |
O
OrbiMed
New York
|
+$1.52M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$1.47M |
| 4 |
Renaissance Technologies
New York
|
+$1.24M |
| 5 |
JP Morgan Chase
New York
|
+$759K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$31.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.83M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.79M |
| 4 |
Morgan Stanley
New York
|
-$3.66M |
| 5 |
BlackRock
New York
|
-$819K |
PASG Hedge Fund Activity: Q1 2022 in Review
108 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q1 2022, worth a combined $133M — down 52% from $278M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PASG positions and 15 closed out — a net gain of 9 holders — while 34 added to existing stakes and 30 trimmed.
The largest buyer was Erste Asset Management, adding an estimated $2M. The largest seller was Frazier Management, exiting entirely with an estimated $31.8M sold.
- 108 institutional investors held Passage Bio (PASG) as of Q1 2022, up from 99 in Q4 2021.
- Funds reported $133M of Passage Bio stock for Q1 2022, down 52% quarter-over-quarter.
- 24 funds opened new Passage Bio positions in Q1 2022 and 15 closed out, a net change of +9 holders.
- The largest Passage Bio buyer in Q1 2022 was Erste Asset Management, an estimated $2M added.
- The largest Passage Bio seller in Q1 2022 was Frazier Management, an estimated $31.8M sold.
Based on aggregated 13F filings for Q1 2022.